Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

A retrospective audit of outcomes of carboplatin/paclitaxel chemoradiation for esophageal cancer (#186)

Rita McMorrow 1 , Sarat Chander 2 , Michael Ng 3 , Rachel Wong 1
  1. Department of Medical Oncology, Eastern Health, Box Hill
  2. Department of Radiation Oncology, Peter MacCallum, Box Hill
  3. Radiation Oncology Victoria, Ringwood


Oesophageal cancer is the eighth most common cancer worldwide. Preoperative chemoradiotherapy (CRT) using carboplatin/paclitaxel improves survival among patients with potentially curable oesophageal or oesophagogastric-junction cancer. This retrospective audit investigated patients treated with neoadjuvant or definitive carboplatin/paclitaxel-based CRT, evaluating survival outcomes and recurrence patterns at our institution.


A retrospective audit was conducted with approval from the Eastern Health ethics committee (QA97-2016). The medical records database was used to identify patients receiving CRT using carboplatin/paclitaxel as defined by the CROSS protocol between May 2014 and December 2016. Data was collected on pre-specified parameters including: basic demographics, histology, treatment response, completion rates, time from diagnosis to disease recurrence, site of disease recurrence, subsequent treatment and survival.


A total of 26 patients were identified. 65% of patents had adenocarcinoma and 35% squamous cell carcinoma. Of the 26 patients, 14 were receiving neoadjuvant chemoradiotherapy while 12 had definitive treatment, 3 of whom had local relapse and were having salvage definitive CRT.

All bar 2 patients completed planned treatment; one due to oesophageal fistula formation and one due to poor tolerance - these were excluded from the analysis of disease recurrence.

With a median follow-up of 17 months (range 7 - 36 months) for the patients who completed treatment, 83% remain alive and 25% (6/24) have recurred. Median time to disease recurrence was 13 months (range 10 - 20 months), 1 patient had isolated nodal recurrence and was treated with radical CRT, 5 had distal metastases.


In this community-based cohort of patients with primary oesophageal or oesophagogastric-junction cancer, carboplatin/paclitaxel was feasible and well tolerated. With median follow-up of 17 months, 75% of patients remain disease free.